San Francisco startup Framework Therapeutics is also engaged on an oral, as soon as-day-to-day GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s expectations in June each time a mid-phase analyze confirmed typical weight loss of around 6% and it strategies to start An addit